Dr. Jack West reviews the remarkable results of the NEJ009 trial that tested the combination of carboplatin/pemetrexed with gefitinib as initial therapy compared to gefitinib followed by chemotherapy in patients with EGFR mutation-positive advanced NSCLC.
Is Chemo the Key to the Best Combination for EGFR Mutation-Positive NSCLC? The Data Too Good to Overlook (BMIC-045)
By Editor